

RealRate

PHARMACEUTICAL 2021

DiaMedica Therapeutics Inc. Rank 85 of 402









PHARMACEUTICAL 2021



RealRate

DiaMedica Therapeutics Inc. Rank 85 of 402

The relative strengths and weaknesses of DiaMedica Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DiaMedica Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 91% points. The greatest weakness of DiaMedica Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 215%, being 168% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	27,921
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,028
Liabilities, Non-Current	53
Other Assets	100
Other Compr. Net Income	-4.0
Other Expenses	27
Other Liabilities	0
Other Net Income	434
Other Revenues	0
Property and Equipment	74
Research and Development	8,310
Selling, General and Administrative Expense	4,389

Output Variable	Value in 1000 USD
Assets	28,095
Liabilities	2,081
Expenses	12,726
Revenues	0
Stockholders Equity	26,014
Net Income	-12,292
Comprehensive Net Income	-12,294
Economic Capital Ratio	215%

